CD138表达水平对不同免疫表型弥漫大B细胞淋巴瘤患者预后临床价值分析  

Clinical value of CD138 expression in prognosis evaluation of diffuse large B cell lymphoma patients with different immunophenotypes

作　　者：郭新建[1] 冶俊玲[1] 苟笑丹[1] 韩静绮[1] 周晓峰[1] GUO Xin-jian;YE Jun-ling;GOU Xiao-dan;HAN Jing-qi;ZHOU Xiao-feng(Department of Pathology,Affiliated Hospital of Qinghai University,Xining 810001,China)

机构地区：[1]青海大学附属医院病理科,青海西宁810001

出　　处：《临床军医杂志》2020年第1期72-74,共3页Clinical Journal of Medical Officers

摘　　要：目的探讨CDl38表达水平对不同免疫表型弥漫大B细胞淋巴瘤(DLBCL)患者预后的临床价值。方法选取自2014年1月至2016年1月就诊的103例DLBCL患者为研究对象。采用免疫组化En Vision法对研究对象的组织标本进行CDl38表达水平的检测,同时测定CD10、MUM1以及bcl-6表达水平辅助完成免疫分型,比较两种免疫学分型患者CD138表达水平的差异,分析患者的存活率,并对CD138与患者总生存期的相关性进行Cox回归分析。结果 GCB型和非GCB型患者分别为53例和50例。GCB型和非GCB型患者在性别、年龄、原发部位、Ann Arbor分期及国际预后指数(IPI)等方面比较,差异均有统计学意义(P <0. 05)。GCB型和非GCB型患者免疫组化检出CD138阳性率分别为15. 1%(8/53)和14. 0%(7/50),差异无统计学意义(P> 0. 05)。GCB型中,CD138阳性患者的生存期为(11. 22±4. 60)个月,1年存活率为35. 8%(19/53);CD138阴性患者的生存期为(16. 92±4. 38)个月,1年存活率为47. 2%(25/53),CD138阳性GCB型患者的生存期,1年存活率均低于CD138阴性GCB型患者,差异有统计学意义(P <0. 05)。在非GCB型中,CD138阳性患者的生存期为(11. 08±4. 41)个月,1年存活率为40. 0%(20/50);CD138阴性非GCB型患者的生存期为(17. 01±4. 57)个月,1年存活率为50. 0%(25/50),CD138阳性非GCB型患者的生存期、1年存活率显著低于CD138阴性非GCB型患者,差异均有统计学意义(P <0. 05)。Cox回归模型分析CD138与患者生存期相关性提示,CD138阳性是生存期降低的危险因素(OR=1. 399,95%可信区间为1. 022~1. 914,P <0. 05)。结论不同免疫分型DLBCL患者CD138阳性状态下生存期、1年生存率均较低;CD138阳性是造成患者生存期短的危险因素。Objective To investigate the clinical value of CD138 expression in prognosis of diffuse large B cell lymphoma( DLBCL)patients with different immunophenotypes. Methods A retrospective study was performed on 103 cases of DLBCL patients who were admitted from January 2014 to January 2016. The specimens were tested for the expression level of CDl38 with immunohistochemistry En Vision method. Immunophenotypes were performed on CD10,MUM1 and bcl-6. The differences of CD138 expression levels between the two immunological subtypes were compared. The survival rates and the correlation between CD138 and overall survival was analyzed by COX regression. Results There were 53 cases of GCB patients and 50 cases of non-GCB patients. There were statistically significant differences between GCB and non-GCB patients in terms of gender,age,primary site,Ann Arbor stage and international prognostic index( IPI),( P < 0. 05). The positive rates of CD138 positive in GCB and non-GCB patients were 15. 1%( 8/53) and14. 0%( 7/50),respectively,and the differences were not statistically significant( P > 0. 05). In GCB patients,the disease-free survival of CD138 positive patients was( 11. 22 ± 4. 60) months,1-year survival rate was 35. 8%( 19/53);the disease-free survival of CD138 negative patients was( 16. 92 ± 4. 38) months,1-year survival rate was 47. 2%( 25/53);the disease-free survival and 1-year survival rate in CD138 positive patients were lower than those in CD138 negative patients( P < 0. 05). In non-GCB patients,the disease-free survival in CD138 positive patients was( 11. 08 ± 4. 41) months,1-year survival rate was 40. 0%( 20/50);the disease-free survival in CD138 negative patients was( 17. 01 ± 4. 57) months,1-year survival rate was 50. 0%( 25/50);the disease-free survival and 1-year survival rate in CD138 positive non-GCB patients were significantly lower than those in CD138 negative non-GCB patients( P < 0. 05).Cox regression analysis showed the correlation between CD138 and the survival period of patients,CD138 positive was

关 键 词：弥漫大B细胞淋巴瘤 免疫分型 CD138 预后 

分 类 号：R733.1[医药卫生—肿瘤]